Prospective, open-label, observational study to evaluate the safety and feasibility of using pulmonary artery pressure (PAP) monitors and wearable activity monitors in patients with pulmonary hypertension (PH).
Diagnosis of pulmonary hypertension (Group I,II,III and IV)
Age 18 years
Estimated glomerular filtration rate (eGFR) > 25
Body mass index (BMI) < 35 (or equivalent)
Group IV PH
Active infection
Pulmonary embolus (PE) or deep vein thrombosis (DVT)
Major cardiovascular event within past 2 months
Patients with a confirmed diagnosis of PH at right heart catheterisation (RHC) and New York Heart Association (NYHA) class III, prior admission for treatment of heart failure.
Cohort
Prospective
CardioMEMS HF System
DeviceThe CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
Activity Monitors
To test the safety and feasibility of pressure monitoring and wearable activity monitors in patients with PH.
Pulmonary Artery Pressure
To correlate Pulmonary Artery Pressure changes with outcome and activity data.
Click on the lead sponsor to view all of their trials.
